Labetuzumab

DB05097InvestigationalProtein Based Therapies

Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

Mechanism: labetuzumab could significantly increase the chemosensitivity of human colon and breast cancer cells in vitro to several anticancer drugs.
Curator reviewed
Primary indication: Labetuzumab is a humanized monoclonal antibody used to treat cancer.Curator reviewed
Also known as: hMN-14 · MAb hMN14 · MN14 monoclonal antibody to carcinoembryonic antigen · Monoclonal antibody hMN-14
Code names: IMMU-100

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

421Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Labetuzumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.